Compare WGS & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WGS | FSK |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Investment Managers |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2020 | 2008 |
| Metric | WGS | FSK |
|---|---|---|
| Price | $70.96 | $11.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 11 |
| Target Price | ★ $90.44 | $12.05 |
| AVG Volume (30 Days) | 645.5K | ★ 1.4M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 18.56% |
| EPS Growth | ★ 62.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $427,539,000.00 | N/A |
| Revenue This Year | $12.70 | N/A |
| Revenue Next Year | $24.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.97 | N/A |
| 52 Week Low | $32.21 | $9.72 |
| 52 Week High | $170.87 | $16.31 |
| Indicator | WGS | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 35.35 |
| Support Level | $71.85 | $10.41 |
| Resistance Level | $94.82 | $11.22 |
| Average True Range (ATR) | 6.64 | 0.25 |
| MACD | -3.00 | -0.08 |
| Stochastic Oscillator | 4.57 | 20.77 |
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.